knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 09:54:43 - browse：49727

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Antibiotic resistance nearly killed me, so I'm raising awareness of it

leisure time

explore

WSS

Why does health care cost so much? A reading guide

Why rehabilitation engineers need to center patients in their research

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Cell therapy fails to slow type 1 diabetes, but safety is established

Adam's Biotech Scorecard: Do Sarepta's exon

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

focus

knowledge

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

After affirmative action ruling, medical educators look to 'holistic review'

H5N1 bird flu virus started spreading in cows in Texas in December

Peter Hotez and the public health issue of online harassment

Health care needs a new profession: neuroimaging counseling

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Adam's Biotech Scorecard: Do Sarepta's exon

23andMe had bad news about my health. I wish a person had delivered it

Dark money group runs ads on China biotech bill

explore

After traumatic brain injury, life support decisions can use more time

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Lab trade group sues FDA to halt regulation of lab

MassMutual is introducing free genetic testing for members

MassMutual is introducing free genetic testing for members

Bird flu in milk supply is likely coming from asymptomatic cows

hotspot

leisure time

explore

focus